US011248031B2

(12) **United States Patent**
Morin et al.

(10) **Patent No.:** US 11,248,031 B2
(45) **Date of Patent:** *Feb. 15, 2022

(54) **METHODS OF TREATING DISEASES ASSOCIATED WITH FIBROSIS USING MODIFIED FGF-21 POLYPEPTIDES**

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**, Princeton, NJ (US)

(72) Inventors: **Paul E. Morin**, Pennington, NJ (US); **Daniel Cohen**, New York, NY (US); **Ranjan Mukherjee**, Churchville, PA (US); **Timothy P. Reilly**, New Hope, PA (US); **Rose C. Christian**, Hopewell, NJ (US); **Dasa Lipovsek**, Cambridge, MA (US); **Ray Camphausen**, Wayland, MA (US); **John Krupinski**, Flemington, NJ (US)

(73) Assignee: **BRISTOL-MYERS SQUIBB COMPANY**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 173 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/455,990**

(22) Filed: **Jun. 28, 2019**

(65) **Prior Publication Data**

US 2019/0382460 A1   Dec. 19, 2019

Related U.S. Application Data

(60) Division of application No. 15/979,881, filed on May 15, 2018, now Pat. No. 10,377,806, which is a division of application No. 15/460,917, filed on Mar. 16, 2017, now Pat. No. 10,189,883, which is a division of application No. 15/215,329, filed on Jul. 20, 2016, now Pat. No. 9,631,004, which is a continuation of application No. 14/921,796, filed on Oct. 23, 2015, now Pat. No. 9,434,778.

(60) Provisional application No. 62/141,383, filed on Apr. 1, 2015, provisional application No. 62/141,337, filed on Apr. 1, 2015, provisional application No. 62/068,526, filed on Oct. 24, 2014, provisional application No. 62/068,523, filed on Oct. 24, 2014, provisional application No. 62/068,514, filed on Oct. 24, 2014, provisional application No. 62/068,296, filed on Oct. 24, 2014, provisional application No. 62/068,534, filed on Oct. 24, 2014.

(51) **Int. Cl.**
A61K 38/18	(2006.01)
C07K 14/50	(2006.01)
A61K 45/06	(2006.01)
A61K 47/60	(2017.01)
A61K 47/64	(2017.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**
CPC *C07K 14/50* (2013.01); *A61K 38/1825* (2013.01); *A61K 45/06* (2013.01); *A61K 47/60* (2017.08); *A61K 47/64* (2017.08); *A61K 38/00* (2013.01); *C07K 2319/00* (2013.01); *C07K 2319/30* (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,968,158 A	1/1961	Ruschig et al.
3,097,242 A	7/1963	Hoehn et al.
3,454,635 A	7/1969	Weber et al.
3,501,495 A	3/1970	Beregi et al.
3,654,357 A	4/1972	Bretschneider et al.
3,668,215 A	6/1972	Plumpe et al.
3,669,966 A	6/1972	Ambrogi et al.
3,708,486 A	1/1973	Kutter et al.
3,773,919 A	11/1973	Boswell et al.
4,287,200 A	9/1981	Kawamatsu et al.
4,289,872 A	9/1981	Denkewaiter et al.
4,412,989 A	11/1983	Iwashita et al.
4,414,148 A	11/1983	Jansen et al.
4,452,747 A	6/1984	Gersonde
4,485,045 A	11/1984	Regen
4,511,502 A	4/1985	Builder et al.
4,511,503 A	4/1985	Olson et al.
4,512,922 A	4/1985	Jones et al.
4,544,545 A	10/1985	Ryan et al.
4,551,433 A	11/1985	Deboer
4,569,789 A	2/1986	Blattler et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU	1740283	2/1984
CA	2300362	2/1999

(Continued)

OTHER PUBLICATIONS

BMS Press Release "Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial" Apr. 2017. 3 pages, https://news.bms.com/press-release/bmy/bristol-myers-squibbs-bms-986036-pegylated-fgf21-shows-consistent-improvement-live.

(Continued)

Primary Examiner — Christine J Saoud
(74) *Attorney, Agent, or Firm* — Robin L. Teskin; Baker, Donelson, Bearman, Caldwell & Berkowitz PC

(57) **ABSTRACT**
Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

22 Claims, 81 Drawing Sheets

Specification includes a Sequence Listing.